Recent Posts

• Testosterone Optimization Therapy (TOT) and Fertility Can Coexist
• FDA’s Shift on Testosterone: A Long-Awaited Reversal
• Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications
• Novo Nordisk asks the FDA to add Semaglutide to the Demonstrably Difficult to Compound list.
• FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of some of these peptides.